His scientific interest is at present focused on Translational Molecular Oncology in lung and breast cancer. Main goals are to optimize EGFR inhibitor treatment in non small cell lung cancer using a panel of NSCLC cell lines. a related goal is to examine the effects of the multi-kinase inhibitor sorafenib in association with the aromatase inhibitor letrozole on cell-survival and proliferation in a panel of breast cancer cells with different expression of ER and ErbB-family tyrosine kinase receptors.